DMPK (Drug Metabolism and Pharmacokinetics) and ADME (Absorption, Distribution, Metabolism, and Excretion) studies are essential in determining the fate and behavior of a drug candidate within the body. These analyses provide valuable insights into a compound's absorption, distribution, metabolism, and elimination, which are crucial in selecting the most promising leads and optimizing their pharmacokinetic properties. At Alfa Cytology, our expertise in DMPK and ADME studies is instrumental in driving the development of novel bladder cancer therapeutics.

Introduction to DMPK/ADME

DMPK studies the how a drug is absorbed, distributed, metabolized, and eliminated by the body, while ADME examines the fundamental processes that govern a drug's behavior in the body. These essential preclinical evaluations provide invaluable insights into a drug candidate's potential efficacy, toxicity, and pharmacokinetic profile. By thoroughly assessing these parameters early in the development process, researchers can make informed decisions about further optimization and progression of drug candidates.

Fig 1. Overview of the main tasks of DMPK support during the different phases of drug discovery. (Reichel A., et al. 2016)

Our Services

At Alfa Cytology, our highly experienced team of scientists offers a comprehensive suite of DMPK and ADME services tailored specifically for bladder cancer drug development. We leverage state-of-the-art analytical techniques, cutting-edge in vitro and in vivo models, and rigorous data analysis to provide our clients with robust and reliable results.

Our services include but are not limited to:

Contact Us

If you're seeking a trusted partner to support your bladder cancer drug development e fforts, look no further than Alfa Cytology. Our team of DMPK/ADME experts is dedicated to working closely with you to design and execute tailored studies that address the unique challenges of your bladder cancer therapeutic candidates. Contact us today to learn more about how we can help you unlock the full potential of your bladder cancer drug pipeline. 

• In Vitro Efficacy Evaluation for Bladder Cancer Therapy
• In Vivo Efficacy Evaluation for Bladder Cancer Therapy
• Toxicology Evaluation for Bladder Cancer Therapy
• In Vitro ADME Services for Bladder Cancer Therapy
• In Vivo ADME Services for Bladder Cancer Therapy
• Metabolite Identification for Bladder Cancer Therapy
• PK/PD Studies for Bladder Cancer Therapy